Tumour mutational burden: clinical utility, challenges and emerging improvements.


Journal

Nature reviews. Clinical oncology
ISSN: 1759-4782
Titre abrégé: Nat Rev Clin Oncol
Pays: England
ID NLM: 101500077

Informations de publication

Date de publication:
27 Aug 2024
Historique:
accepted: 23 07 2024
medline: 28 8 2024
pubmed: 28 8 2024
entrez: 27 8 2024
Statut: aheadofprint

Résumé

Tumour mutational burden (TMB), defined as the total number of somatic non-synonymous mutations present within the cancer genome, varies across and within cancer types. A first wave of retrospective and prospective research identified TMB as a predictive biomarker of response to immune-checkpoint inhibitors and culminated in the disease-agnostic approval of pembrolizumab for patients with TMB-high tumours based on data from the Keynote-158 trial. Although the applicability of outcomes from this trial to all cancer types and the optimal thresholds for TMB are yet to be ascertained, research into TMB is advancing along three principal avenues: enhancement of TMB assessments through rigorous quality control measures within the laboratory process, including the mitigation of confounding factors such as limited panel scope and low tumour purity; refinement of the traditional TMB framework through the incorporation of innovative concepts such as clonal, persistent or HLA-corrected TMB, tumour neoantigen load and mutational signatures; and integration of TMB with established and emerging biomarkers such as PD-L1 expression, microsatellite instability, immune gene expression profiles and the tumour immune contexture. Given its pivotal functions in both the pathogenesis of cancer and the ability of the immune system to recognize tumours, a profound comprehension of the foundational principles and the continued evolution of TMB are of paramount relevance for the field of oncology.

Identifiants

pubmed: 39192001
doi: 10.1038/s41571-024-00932-9
pii: 10.1038/s41571-024-00932-9
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. Springer Nature Limited.

Références

Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000).
pubmed: 10647931 doi: 10.1016/S0092-8674(00)81683-9
Vogelstein, B. & Kinzler, K. W. The multistep nature of cancer. Trends Genet. 9, 138141 (1993).
doi: 10.1016/0168-9525(93)90209-Z
Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546–1558 (2013).
pubmed: 23539594 pmcid: 3749880 doi: 10.1126/science.1235122
Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013).
pubmed: 23945592 pmcid: 3776390 doi: 10.1038/nature12477
Rizvi, N. A. et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124–128 (2015).
pubmed: 25765070 pmcid: 4993154 doi: 10.1126/science.aaa1348
Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189–2199 (2014).
pubmed: 25409260 pmcid: 4315319 doi: 10.1056/NEJMoa1406498
Gandhi, L. et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med. 378, 2078–2092 (2018).
pubmed: 29658856 doi: 10.1056/NEJMoa1801005
Paz-Ares, L. et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N. Engl. J. Med. 379, 2040–2051 (2018).
pubmed: 30280635 doi: 10.1056/NEJMoa1810865
Mok, T. S. K. et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 393, 1819–1830 (2019).
pubmed: 30955977 doi: 10.1016/S0140-6736(18)32409-7
Hellmann, M. D. et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N. Engl. J. Med. 381, 2020–2031 (2019).
pubmed: 31562796 doi: 10.1056/NEJMoa1910231
Chan, T. A. et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann. Oncol. 30, 44–56 (2019).
pubmed: 30395155 doi: 10.1093/annonc/mdy495
Carbone, D. P. et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N. Engl. J. Med. 376, 2415–2426 (2017).
pubmed: 28636851 pmcid: 6487310 doi: 10.1056/NEJMoa1613493
Hellmann, M. D. et al. Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer. Cancer Cell 33, 843–852.e4 (2018).
pubmed: 29657128 pmcid: 5953836 doi: 10.1016/j.ccell.2018.03.018
Hellmann, M. D. et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N. Engl. J. Med. 378, 2093–2104 (2018).
pubmed: 29658845 pmcid: 7193684 doi: 10.1056/NEJMoa1801946
Yarchoan, M., Hopkins, A. & Jaffee, E. M. Tumor mutational burden and response rate to PD-1 inhibition. N. Engl. J. Med. 377, 2500–2501 (2017).
pubmed: 29262275 pmcid: 6549688 doi: 10.1056/NEJMc1713444
Banchereau, R. et al. Molecular determinants of response to PD-L1 blockade across tumor types. Nat. Commun. 12, 3969 (2021).
pubmed: 34172722 pmcid: 8233428 doi: 10.1038/s41467-021-24112-w
Samstein, R. M. et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat. Genet. 51, 202–206 (2019).
pubmed: 30643254 pmcid: 6365097 doi: 10.1038/s41588-018-0312-8
Cao, D., Xu, H., Xu, X., Guo, T. & Ge, W. High tumor mutation burden predicts better efficacy of immunotherapy: a pooled analysis of 103078 cancer patients. Oncoimmunology 8, e1629258 (2019).
pubmed: 31428527 pmcid: 6685508 doi: 10.1080/2162402X.2019.1629258
Ricciuti, B. et al. Association of high tumor mutation burden in non-small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 expression levels. JAMA Oncol. 8, 1160–1168 (2022).
pubmed: 35708671 pmcid: 9204620 doi: 10.1001/jamaoncol.2022.1981
Thummalapalli, R. et al. Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. Clin. Cancer Res. 20, 4408–4418 (2023).
doi: 10.1158/1078-0432.CCR-23-1207
Yarchoan, M. et al. PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. JCI Insight 4, e126908 (2019).
pubmed: 30895946 pmcid: 6482991 doi: 10.1172/jci.insight.126908
Budczies, J. et al. Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burden. Oncoimmunology 7, e1526613 (2018).
pubmed: 30524909 pmcid: 6279340 doi: 10.1080/2162402X.2018.1526613
Krämer, A. et al. Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 34, 228–246 (2023).
pubmed: 36563965 doi: 10.1016/j.annonc.2022.11.013
Ross, J. S. et al. Comprehensive genomic profiling of carcinoma of unknown primary origin: retrospective molecular classification considering the CUPISCO study design. Oncologist 26, e394–e402 (2021).
pubmed: 33219618 doi: 10.1002/onco.13597
Bochtler, T. et al. Prognostic impact of copy number alterations and tumor mutational burden in carcinoma of unknown primary. Genes Chromosomes Cancer 61, 551–560 (2022).
pubmed: 35430765 doi: 10.1002/gcc.23047
Gatalica, Z., Xiu, J., Swensen, J. & Vranic, S. Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy. Eur. J. Cancer 94, 179–186 (2018).
pubmed: 29571084 doi: 10.1016/j.ejca.2018.02.021
Marabelle, A. et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 21, 1353–1365 (2020).
pubmed: 32919526 doi: 10.1016/S1470-2045(20)30445-9
Pouyiourou, M. et al. Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial. Nat. Commun. 14, 6761 (2023).
pubmed: 37875494 pmcid: 10598029 doi: 10.1038/s41467-023-42400-5
Krämer, A. et al. Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study. Lancet 404, 527–539 (2024).
pubmed: 39096924 doi: 10.1016/S0140-6736(24)00814-6
Gandara, D. R. et al. Tumor mutational burden (TMB) measurement from an FDA-approved assay and real-world overall survival (rwOS) on single-agent immune checkpoint inhibitors (ICI) in over 8,000 patients across 24 cancer types. J. Clin. Oncol. 41, 2503 (2023).
doi: 10.1200/JCO.2023.41.16_suppl.2503
Davis, A. A. et al. Comparison of tumor mutational burden (TMB) across tumor tissue and circulating tumor DNA (ctDNA). J. Clin. Oncol. 35, e23028 (2017).
doi: 10.1200/JCO.2017.35.15_suppl.e23028
Gandara, D. R. et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat. Med. 24, 1441–1448 (2018).
pubmed: 30082870 doi: 10.1038/s41591-018-0134-3
Wang, Z. et al. Assessment of blood tumor mutational burden as a potential biomarker for immunotherapy in patients with non-small cell lung cancer with use of a next-generation sequencing cancer gene panel. JAMA Oncol. 5, 696–702 (2019).
pubmed: 30816954 pmcid: 6512308 doi: 10.1001/jamaoncol.2018.7098
Si, H. et al. A blood-based assay for assessment of tumor mutational burden in firstline metastatic NSCLC treatment: results from the MYSTIC study. Clin. Cancer Res. 27, 1631–1640 (2021).
pubmed: 33355200 doi: 10.1158/1078-0432.CCR-20-3771
Peters, S. et al. Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial. Nat. Med. 28, 1831–1839 (2022).
pubmed: 35995953 pmcid: 9499854 doi: 10.1038/s41591-022-01933-w
Prasad, V. & Addeo, A. The FDA approval of pembrolizumab for patients with TMB >10 mut/Mb: was it a wise decision? No. Ann. Oncol. 31, 1112–1114 (2020).
pubmed: 32771305 doi: 10.1016/j.annonc.2020.07.001
Subbiah, V., Solit, D. B., Chan, T. A. & Kurzrock, R. The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥ 10: a decision centered on empowering patients and their physicians. Ann. Oncol. 31, 1115–1118 (2020).
pubmed: 32771306 doi: 10.1016/j.annonc.2020.07.002
Chang, H. et al. Bioinformatic methods and bridging of assay results for reliable tumor mutational burden assessment in non-small-cell lung cancer. Mol. Diagn. Ther. 23, 507–520 (2019).
pubmed: 31250328 pmcid: 6675777 doi: 10.1007/s40291-019-00408-y
Vega, D. M. et al. Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project. Ann. Oncol. 32, 1626–1636 (2021).
pubmed: 34606929 doi: 10.1016/j.annonc.2021.09.016
Stenzinger, A. et al. Harmonization and standardization of panel-based tumor mutational burden measurement: real-world results and recommendations of the quality in pathology study. J. Thorac. Oncol. 15, 1177–1189 (2020).
pubmed: 32119917 doi: 10.1016/j.jtho.2020.01.023
Budczies, J. et al. Optimizing panel-based tumor mutational burden (TMB) measurement. Ann. Oncol. 30, 1496–1506 (2019).
pubmed: 31268125 doi: 10.1093/annonc/mdz205
Turajlic, S. et al. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncol. 18, 1009–1021 (2017).
pubmed: 28694034 doi: 10.1016/S1470-2045(17)30516-8
Kloor, M. & von Knebel Doeberitz, M. The immune biology of microsatellite-unstable cancer. Trends Cancer 2, 121–133 (2016).
pubmed: 28741532 doi: 10.1016/j.trecan.2016.02.004
Tomasetti, C., Vogelstein, B. & Parmigiani, G. Half or more of the somatic mutations in cancers of self-renewing tissues originate prior to tumor initiation. Proc. Natl Acad. Sci. USA 110, 1999–2004 (2013).
pubmed: 23345422 pmcid: 3568331 doi: 10.1073/pnas.1221068110
Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214–218 (2013).
pubmed: 23770567 pmcid: 3919509 doi: 10.1038/nature12213
Merino, D. M. et al. Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project. J. Immunother. Cancer 8, e000147 (2020).
pubmed: 32217756 pmcid: 7174078 doi: 10.1136/jitc-2019-000147
Menzel, M. et al. Multicentric pilot study to standardize clinical whole exome sequencing (WES) for cancer patients. npj Precis. Oncol. 7, 106 (2023).
pubmed: 37864096 pmcid: 10589320 doi: 10.1038/s41698-023-00457-x
Rosenthal, R. et al. Neoantigen-directed immune escape in lung cancer evolution. Nature 567, 479–485 (2019).
pubmed: 30894752 pmcid: 6954100 doi: 10.1038/s41586-019-1032-7
Kazdal, D. et al. Spatial and temporal heterogeneity of panel-based tumor mutational burden in pulmonary adenocarcinoma: separating biology from technical artifacts. J. Thorac. Oncol. 14, 1935–1947 (2019).
pubmed: 31349062 doi: 10.1016/j.jtho.2019.07.006
Anagnostou, V. et al. Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer. Nat. Cancer 1, 99–111 (2020).
pubmed: 32984843 pmcid: 7514475 doi: 10.1038/s43018-019-0008-8
Karczewski, K. J. et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 581, 434–443 (2020).
pubmed: 32461654 pmcid: 7334197 doi: 10.1038/s41586-020-2308-7
Nassar, A. H. et al. Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors. Cancer Cell 40, 1161–1172.e5 (2022).
pubmed: 36179682 pmcid: 9559771 doi: 10.1016/j.ccell.2022.08.022
Huang, R. S. P., Graf, R. P. & Oxnard, G. R. Not all TMB assays are the same: clinical validity of robust algorithmic germline filtering. Cancer Cell 41, 819–820 (2023).
pubmed: 37059103 doi: 10.1016/j.ccell.2023.03.017
Buchhalter, I. et al. Size matters: dissecting key parameters for panel-based tumor mutational burden analysis. Int. J. Cancer 144, 848–858 (2019).
pubmed: 30238975 doi: 10.1002/ijc.31878
Budczies, J. et al. Quantifying potential confounders of panel-based tumor mutational burden (TMB) measurement. Lung Cancer 142, 114–119 (2020).
pubmed: 32143116 doi: 10.1016/j.lungcan.2020.01.019
Osipov, A. et al. Tumor mutational burden, toxicity, and response of immune checkpoint inhibitors targeting PD(L)1, CTLA-4, and combination: a meta-regression analysis. Clin. Cancer Res. 26, 4842–4851 (2020).
pubmed: 32586938 pmcid: 7501151 doi: 10.1158/1078-0432.CCR-20-0458
Sneddon, S. et al. Identification of a CD8+ T-cell response to a predicted neoantigen in malignant mesothelioma. Oncoimmunology 9, 1684713 (2020).
pubmed: 32002298 doi: 10.1080/2162402X.2019.1684713
Ros, J. et al. Immunotherapy for colorectal cancer with high microsatellite instability: the ongoing search for biomarkers. Cancers 15, 4245 (2023).
pubmed: 37686520 pmcid: 10486610 doi: 10.3390/cancers15174245
Rousseau, B. et al. The spectrum of benefit from checkpoint blockade in hypermutated tumors. N. Engl. J. Med. 384, 1168–1170 (2021).
pubmed: 33761214 pmcid: 8403269 doi: 10.1056/NEJMc2031965
Mcgrail, D. J. et al. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann. Oncol. 32, 661–672 (2021).
pubmed: 33736924 doi: 10.1016/j.annonc.2021.02.006
Ready, N. et al. First-line nivolumab plus ipilimumab in advanced non-small-cell lung cancer (CheckMate 568): outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers. J. Clin. Oncol. 37, 992–1000 (2019).
pubmed: 30785829 pmcid: 6494267 doi: 10.1200/JCO.18.01042
Kwon, M. et al. Determinants of response and intrinsic resistance to PD-1 blockade in microsatellite instability-high gastric cancer. Cancer Discov. 11, 2168–2185 (2021).
pubmed: 33846173 doi: 10.1158/2159-8290.CD-21-0219
Mandal, R. et al. Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response. Science 364, 485–491 (2019).
pubmed: 31048490 pmcid: 6685207 doi: 10.1126/science.aau0447
Schrock, A. B. et al. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. Ann. Oncol. 30, 10961103 (2019).
doi: 10.1093/annonc/mdz134
Loupakis, F. et al. Prediction of benefit from checkpoint inhibitors in mismatch repair deficient metastatic colorectal cancer: role of tumor infiltrating lymphocytes. Oncologist 25, 481–487 (2020).
pubmed: 31967692 pmcid: 7288636 doi: 10.1634/theoncologist.2019-0611
Cohen, R. et al. Association of primary resistance to immune checkpoint inhibitors in metastatic colorectal cancer with misdiagnosis of microsatellite instability or mismatch repair deficiency status. JAMA Oncol. 5, 551–555 (2019).
pubmed: 30452494 doi: 10.1001/jamaoncol.2018.4942
Paz-Ares, L. et al. Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407. Ann. Oncol. 30, v917–v918 (2019).
doi: 10.1093/annonc/mdz394.078
Langer, C. et al. OA04.05 KEYNOTE-021: TMB and outcomes for carboplatin and pemetrexed with or without pembrolizumab for nonsquamous NSCLC. J. Thorac. Oncol. https://doi.org/10.1016/j.jtho.2019.08.426 (2019).
Garassino, M. C. et al. Evaluation of blood TMB (bTMB) in KEYNOTE-189: pembrolizumab (pembro) plus chemotherapy (chemo) with pemetrexed and platinum versus placebo plus chemo as first-line therapy for metastatic nonsquamous NSCLC. J. Clin. Oncol. 38, 9521–9521 (2020).
doi: 10.1200/JCO.2020.38.15_suppl.9521
Mountzios, G. et al. Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer. ESMO Open 6, 100254 (2021).
pubmed: 34481329 pmcid: 8417333 doi: 10.1016/j.esmoop.2021.100254
Alessi, J. V. et al. Clinicopathologic and genomic factors impacting efficacy of firstline chemoimmunotherapy in advanced NSCLC. J. Thorac. Oncol. 18, 731–743 (2023).
pubmed: 36775193 pmcid: 10500613 doi: 10.1016/j.jtho.2023.01.091
Giannakis, M. et al. Genomic correlates of immune-cell infiltrates in colorectal carcinoma. Cell Rep. 15, 857–865 (2016).
pubmed: 27149842 pmcid: 4850357 doi: 10.1016/j.celrep.2016.03.075
Wang, P., Chen, Y. & Wang, C. Beyond tumor mutation burden: tumor neoantigen burden as a biomarker for immunotherapy and other types of therapy. Front. Oncol. 11, 672677 (2021).
pubmed: 33996601 pmcid: 8117238 doi: 10.3389/fonc.2021.672677
Rock, K. L., Reits, E. & Neefjes, J. Present yourself! By MHC class I and MHC class II molecules. Trends Immunol. 37, 724–737 (2016).
pubmed: 27614798 pmcid: 5159193 doi: 10.1016/j.it.2016.08.010
Neefjes, J., Jongsma, M. L., Paul, P. & Bakke, O. Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat. Rev. Immunol. 11, 823–836 (2011).
pubmed: 22076556 doi: 10.1038/nri3084
Jongsma, M. L. M., Neefjes, J. & Spaapen, R. M. Playing hide and seek: tumor cells in control of MHC class I antigen presentation. Mol. Immunol. 136, 36–44 (2021).
pubmed: 34082257 doi: 10.1016/j.molimm.2021.05.009
Macy, A. M., Herrmann, L. M., Adams, A. C. & Hastings, K. T. Major histocompatibility complex class II in the tumor microenvironment: functions of nonprofessional antigen-presenting cells. Curr. Opin. Immunol. 83, 102330 (2023).
pubmed: 37130456 pmcid: 10524529 doi: 10.1016/j.coi.2023.102330
Bawden, E. & Gebhardt, T. The multifaceted roles of CD4(+) T cells and MHC class II in cancer surveillance. Curr. Opin. Immunol. 83, 102345 (2023).
pubmed: 37245413 doi: 10.1016/j.coi.2023.102345
Richters, M. M. et al. Best practices for bioinformatic characterization of neoantigens for clinical utility. Genome Med. 11, 56 (2019).
pubmed: 31462330 pmcid: 6714459 doi: 10.1186/s13073-019-0666-2
Fotakis, G., Trajanoski, Z. & Rieder, D. Computational cancer neoantigen prediction: current status and recent advances. Immunooncol. Technol. 12, 100052 (2021).
pubmed: 35755950 pmcid: 9216660 doi: 10.1016/j.iotech.2021.100052
Vita, R. et al. The Immune Epitope Database (IEDB): 2018 update. Nucleic Acids Res. 47, D339–D343 (2019).
pubmed: 30357391 doi: 10.1093/nar/gky1006
Shao, W., Caron, E., Pedrioli, P. & Aebersold, R. The SysteMHC Atlas: a computational pipeline, a website, and a data repository for immunopeptidomic analyses. Methods Mol. Biol. 2120, 173–181 (2020).
pubmed: 32124319 doi: 10.1007/978-1-0716-0327-7_12
Perez-Riverol, Y. et al. The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences. Nucleic Acids Res. 50, D543–D552 (2022).
pubmed: 34723319 doi: 10.1093/nar/gkab1038
Andreatta, M. & Nielsen, M. Gapped sequence alignment using artificial neural networks: application to the MHC class I system. Bioinformatics 32, 511–517 (2016).
pubmed: 26515819 doi: 10.1093/bioinformatics/btv639
O’Donnell, T. J. et al. MHCflurry: open-source class I MHC binding affinity prediction. Cell Syst. 7, 129–132.e4 (2018).
pubmed: 29960884 doi: 10.1016/j.cels.2018.05.014
Reynisson, B., Alvarez, B., Paul, S., Peters, B. & Nielsen, M. NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res. 48, W449–W454 (2020).
pubmed: 32406916 pmcid: 7319546 doi: 10.1093/nar/gkaa379
O’Donnell, T. J., Rubinsteyn, A. & Laserson, U. MHCflurry 2.0: improved pan-allele prediction of MHC class I-presented peptides by incorporating antigen processing. Cell Syst. 11, 418–419 (2020).
pubmed: 33091335 doi: 10.1016/j.cels.2020.09.001
Shim, J. H. et al. HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients. Ann. Oncol. 31, 902–911 (2020).
pubmed: 32320754 doi: 10.1016/j.annonc.2020.04.004
Ghorani, E. et al. Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanoma. Ann. Oncol. 29, 271–279 (2018).
pubmed: 29361136 doi: 10.1093/annonc/mdx687
Balachandran, V. P. et al. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature 551, 512–516 (2017).
pubmed: 29132146 pmcid: 6145146 doi: 10.1038/nature24462
Luksza, M. et al. A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy. Nature 551, 517–520 (2017).
pubmed: 29132144 pmcid: 6137806 doi: 10.1038/nature24473
Litchfield, K. et al. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell 184, 596–614 e514 (2021).
pubmed: 33508232 pmcid: 7933824 doi: 10.1016/j.cell.2021.01.002
Luksza, M. et al. Neoantigen quality predicts immunoediting in survivors of pancreatic cancer. Nature 606, 389–395 (2022).
pubmed: 35589842 pmcid: 9177421 doi: 10.1038/s41586-022-04735-9
Wells, D. K. et al. Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction. Cell 183, 818–834.e13 (2020).
pubmed: 33038342 pmcid: 7652061 doi: 10.1016/j.cell.2020.09.015
Rojas, L. A. et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618, 144–150 (2023).
pubmed: 37165196 pmcid: 10171177 doi: 10.1038/s41586-023-06063-y
Weber, J. S. et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet 403, 632–644 (2024).
pubmed: 38246194 doi: 10.1016/S0140-6736(23)02268-7
Oreper, D., Klaeger, S., Jhunjhunwala, S. & Delamarre, L. The peptide woods are lovely, dark and deep: hunting for novel cancer antigens. Semin. Immunol. 67, 101758 (2023).
pubmed: 37027981 doi: 10.1016/j.smim.2023.101758
Ng, K. W. et al. Antibodies against endogenous retroviruses promote lung cancer immunotherapy. Nature 616, 563–573 (2023).
pubmed: 37046094 pmcid: 10115647 doi: 10.1038/s41586-023-05771-9
Panda, A. et al. Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma. JCI Insight 3, e121522 (2018).
pubmed: 30135306 pmcid: 6141170 doi: 10.1172/jci.insight.121522
McGranahan, N. et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351, 1463–1469 (2016).
pubmed: 26940869 pmcid: 4984254 doi: 10.1126/science.aaf1490
Wolf, Y. et al. UVB-induced tumor heterogeneity diminishes immune response in melanoma. Cell 179, 219–235.e21 (2019).
pubmed: 31522890 pmcid: 6863386 doi: 10.1016/j.cell.2019.08.032
Boll, L. M. et al. The impact of mutational clonality in predicting the response to immune checkpoint inhibitors in advanced urothelial cancer. Sci. Rep. 13, 15287 (2023).
pubmed: 37714872 pmcid: 10504302 doi: 10.1038/s41598-023-42495-2
Westcott, P. M. K. et al. Mismatch repair deficiency is not sufficient to elicit tumor immunogenicity. Nat. Genet. 55, 1686–1695 (2023).
pubmed: 37709863 pmcid: 10562252 doi: 10.1038/s41588-023-01499-4
Ravi, A. et al. Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer. Nat. Genet. 55, 807–819 (2023).
pubmed: 37024582 pmcid: 10181943 doi: 10.1038/s41588-023-01355-5
Freeman, S. S. et al. Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma. Cell Rep. Med. 3, 100500 (2022).
pubmed: 35243413 pmcid: 8861826 doi: 10.1016/j.xcrm.2021.100500
Niknafs, N. et al. Persistent mutation burden drives sustained anti-tumor immune responses. Nat. Med. 29, 440–449 (2023).
pubmed: 36702947 pmcid: 9941047 doi: 10.1038/s41591-022-02163-w
Anagnostou, V. et al. Integrative tumor and immune cell multi-omic analyses predict response to immune checkpoint blockade in melanoma. Cell Rep. Med. 1, 100139 (2020).
pubmed: 33294860 pmcid: 7691441 doi: 10.1016/j.xcrm.2020.100139
Markham, J. F. et al. Predicting response to immune checkpoint blockade in NSCLC with tumour-only RNA-seq. Br. J. Cancer 128, 1148–1154 (2023).
pubmed: 36572732 doi: 10.1038/s41416-022-02105-w
Szeto, C. et al. High correlation between TMB, expressed TMB, and neoantigen load using tumor: normal whole exome DNA and matched whole transcriptome RNA sequencing. J. Clin. Oncol. 38, e15238 (2020).
doi: 10.1200/JCO.2020.38.15_suppl.e15238
DiGuardo, M. A. et al. RNA-seq reveals differences in expressed tumor mutation burden in colorectal and endometrial cancers with and without defective DNA-mismatch repair. J. Mol. Diagn. 23, 555–564 (2021).
pubmed: 33549857 doi: 10.1016/j.jmoldx.2021.01.008
Sorokin, M. et al. RNA sequencing data for FFPE tumor blocks can be used for robust estimation of tumor mutation burden in individual biosamples. Front. Oncol. 11, 732644 (2021).
pubmed: 34650919 pmcid: 8506044 doi: 10.3389/fonc.2021.732644
Alexandrov, L. B. et al. The repertoire of mutational signatures in human cancer. Nature 578, 94–101 (2020).
pubmed: 32025018 pmcid: 7054213 doi: 10.1038/s41586-020-1943-3
Alexandrov, L. B., Nik-Zainal, S., Wedge, D. C., Campbell, P. J. & Stratton, M. R. Deciphering signatures of mutational processes operative in human cancer. Cell Rep. 3, 246–259 (2013).
pubmed: 23318258 pmcid: 3588146 doi: 10.1016/j.celrep.2012.12.008
Degasperi, A. et al. Substitution mutational signatures in whole-genome-sequenced cancers in the UK population. Science https://doi.org/10.1126/science.abl9283 (2022).
Nik-Zainal, S. et al. Mutational processes molding the genomes of 21 breast cancers. Cell 149, 979–993 (2012).
pubmed: 22608084 pmcid: 3414841 doi: 10.1016/j.cell.2012.04.024
Sha, D. et al. Tumor mutational burden as a predictive biomarker in solid tumors. Cancer Discov. 10, 1808–1825 (2020).
pubmed: 33139244 pmcid: 7710563 doi: 10.1158/2159-8290.CD-20-0522
The COSMIC Database v3.4. https://cancer.sanger.ac.uk/signatures/ (2023).
Zhao, E. Y. et al. Homologous recombination deficiency and platinum-based therapy outcomes in advanced breast cancer. Clin. Cancer Res. 23, 7521–7530 (2017).
pubmed: 29246904 doi: 10.1158/1078-0432.CCR-17-1941
Davies, H. et al. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nat. Med. 23, 517–525 (2017).
pubmed: 28288110 pmcid: 5833945 doi: 10.1038/nm.4292
Nguyen, L., Martens, J. W. M., Van Hoeck, A. & Cuppen, E. Pan-cancer landscape of homologous recombination deficiency. Nat. Commun. 11, 5584 (2020).
pubmed: 33149131 pmcid: 7643118 doi: 10.1038/s41467-020-19406-4
Secrier, M. et al. Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. Nat. Genet. 48, 1131–1141 (2016).
pubmed: 27595477 pmcid: 5957269 doi: 10.1038/ng.3659
Petrelli, A. et al. BRCA2 germline mutations identify gastric cancers responsive to PARP inhibitors. Cancer Res. 83, 1699–1710 (2023).
pubmed: 37129948 pmcid: 10183806 doi: 10.1158/0008-5472.CAN-22-2620
Peng, G. et al. Genome-wide transcriptome profiling of homologous recombination DNA repair. Nat. Commun. 5, 3361 (2014).
pubmed: 24553445 doi: 10.1038/ncomms4361
Li, H. et al. PARP inhibitor resistance: the underlying mechanisms and clinical implications. Mol. Cancer 19, 107 (2020).
pubmed: 32563252 pmcid: 7305609 doi: 10.1186/s12943-020-01227-0
Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509–2520 (2015).
pubmed: 26028255 pmcid: 4481136 doi: 10.1056/NEJMoa1500596
Le, D. T. et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357, 409–413 (2017).
pubmed: 28596308 pmcid: 5576142 doi: 10.1126/science.aan6733
Marabelle, A. et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J. Clin. Oncol. 38, 1–10 (2020).
pubmed: 31682550 doi: 10.1200/JCO.19.02105
Touat, M. et al. Mechanisms and therapeutic implications of hypermutation in gliomas. Nature 580, 517–523 (2020).
pubmed: 32322066 pmcid: 8235024 doi: 10.1038/s41586-020-2209-9
Chen, H. et al. The immune response-related mutational signatures and driver genes in non-small-cell lung cancer. Cancer Sci. 110, 2348–2356 (2019).
pubmed: 31222843 pmcid: 6676111 doi: 10.1111/cas.14113
Miao, D. et al. Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nat. Genet. 50, 1271–1281 (2018).
pubmed: 30150660 pmcid: 6119118 doi: 10.1038/s41588-018-0200-2
Wang, S., Jia, M., He, Z. & Liu, X. S. APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer. Oncogene 37, 3924–3936 (2018).
pubmed: 29695832 pmcid: 6053356 doi: 10.1038/s41388-018-0245-9
Liao, J. et al. Clinical and genomic characterization of mutational signatures across human cancers. Int. J. Cancer 152, 1613–1629 (2023).
pubmed: 36533638 doi: 10.1002/ijc.34402
Chong, W. et al. Association of clock-like mutational signature with immune checkpoint inhibitor outcome in patients with melanoma and NSCLC. Mol. Ther. Nucleic Acids 23, 89–100 (2021).
pubmed: 33335795 doi: 10.1016/j.omtn.2020.10.033
Valero, C. et al. Clinical-genomic determinants of immune checkpoint blockade response in head and neck squamous cell carcinoma. J. Clin. Invest. 133, e169823 (2023).
pubmed: 37561583 pmcid: 10541199 doi: 10.1172/JCI169823
Koh, G., Degasperi, A., Zou, X., Momen, S. & Nik-Zainal, S. Mutational signatures: 1267 emerging concepts, caveats and clinical applications. Nat. Rev. Cancer 21, 619–637 (2021).
pubmed: 34316057 doi: 10.1038/s41568-021-00377-7
NIH. The cost of sequencing a human genome. genome.gov https://www.genome.gov/about-genomics/fact-sheets/Sequencing-Human-Genome-cost (2021).
Newell, F. et al. Multiomic profiling of checkpoint inhibitor-treated melanoma: identifying predictors of response and resistance, and markers of biological discordance. Cancer Cell 40, 88–102.e7 (2022).
pubmed: 34951955 doi: 10.1016/j.ccell.2021.11.012
Liu, D. et al. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nat. Med. 25, 1916–1927 (2019).
pubmed: 31792460 pmcid: 6898788 doi: 10.1038/s41591-019-0654-5
Forde, P. M. et al. Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial. Nat. Med. 27, 1910–1920 (2021).
pubmed: 34750557 pmcid: 8604731 doi: 10.1038/s41591-021-01541-0
Anagnostou, V., Landon, B. V., Medina, J. E., Forde, P. & Velculescu, V. E. Translating the evolving molecular landscape of tumors to biomarkers of response for cancer immunotherapy. Sci. Transl. Med. 14, eabo3958 (2022).
pubmed: 36350985 pmcid: 9844537 doi: 10.1126/scitranslmed.abo3958
Sinha, N. et al. Immune determinants of the association between tumor mutational burden and immunotherapy response across cancer types. Cancer Res. 82, 20762083 (2022).
doi: 10.1158/0008-5472.CAN-21-2542
Danaher, P. et al. Gene expression markers of tumor infiltrating leukocytes. J. Immunother. Cancer 5, 18 (2017).
pubmed: 28239471 pmcid: 5319024 doi: 10.1186/s40425-017-0215-8
Cristescu, R. et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science 362, eaar3593 (2018).
pubmed: 30309915 pmcid: 6718162 doi: 10.1126/science.aar3593
Goodman, A. M. et al. MHC-I genotype and tumor mutational burden predict response to immunotherapy. Genome Med. 12, 45 (2020).
pubmed: 32430031 pmcid: 7236948 doi: 10.1186/s13073-020-00743-4
Han, J. et al. Pan-cancer analysis reveals sex-specific signatures in the tumor microenvironment. Mol. Oncol. 16, 2153–2173 (2022).
pubmed: 35229456 pmcid: 9168759 doi: 10.1002/1878-0261.13203
Lee, J. S. & Ruppin, E. Multiomics prediction of response rates to therapies to inhibit programmed cell death 1 and programmed cell death 1 ligand 1. JAMA Oncol. 5, 1614–1618 (2019).
pubmed: 31436822 pmcid: 6707018 doi: 10.1001/jamaoncol.2019.2311
Stenzinger, A., Kazdal, D. & Peters, S. Strength in numbers: predicting response to checkpoint inhibitors from large clinical datasets. Cell 184, 571–573 (2021).
pubmed: 33508231 doi: 10.1016/j.cell.2021.01.008
Mason, M. et al. A community challenge to predict clinical outcomes after immune checkpoint blockade in non-small cell lung cancer. J. Transl. Med. 22, 190 (2024).
pubmed: 38383458 pmcid: 10880244 doi: 10.1186/s12967-023-04705-3
Gajic, Z. Z., Deshpande, A., Legut, M., Imielinski, M. & Sanjana, N. E. Recurrent somatic mutations as predictors of immunotherapy response. Nat. Commun. 13, 3938 (2022).
pubmed: 35803911 pmcid: 9270330 doi: 10.1038/s41467-022-31055-3
Wang, J. et al. Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study. Lancet Oncol. 24, 151–161 (2023).
pubmed: 36681091 pmcid: 10599647 doi: 10.1016/S1470-2045(22)00783-5
Colle, R. et al. BRAF V600E/RAS mutations and Lynch syndrome in patients with MSIH/dMMR metastatic colorectal cancer treated with immune checkpoint inhibitors. Oncologist 28, 771–779 (2023).
pubmed: 37023721 pmcid: 10485382 doi: 10.1093/oncolo/oyad082
Liu, G. C. et al. The heterogeneity between Lynch-associated and sporadic MMR deficiency in colorectal cancers. J. Natl Cancer Inst. 110, 975–984 (2018).
pubmed: 29471527 doi: 10.1093/jnci/djy004
Ratovomanana, T. et al. Prediction of response to immune checkpoint blockade in patients with metastatic colorectal cancer with microsatellite instability. Ann. Oncol. 34, 703–713 (2023).
pubmed: 37269904 doi: 10.1016/j.annonc.2023.05.010
Zhang, J. et al. The combination of neoantigen quality and T lymphocyte infiltrates identifies glioblastomas with the longest survival. Commun. Biol. 2, 135 (2019).
pubmed: 31044160 pmcid: 6478916 doi: 10.1038/s42003-019-0369-7
Sade-Feldman, M. et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat. Commun. 8, 1136 (2017).
pubmed: 29070816 pmcid: 5656607 doi: 10.1038/s41467-017-01062-w
Sucker, A. et al. Genetic evolution of T-cell resistance in the course of melanoma progression. Clin. Cancer Res. 20, 6593–6604 (2014).
pubmed: 25294904 pmcid: 8728890 doi: 10.1158/1078-0432.CCR-14-0567
Mumphrey, M. B. et al. Distinct mutational processes shape selection of MHC class I and class II mutations across primary and metastatic tumors. Cell Rep. 42, 112965 (2023).
pubmed: 37597185 doi: 10.1016/j.celrep.2023.112965
Middha, S. et al. Majority of B2M-mutant and -deficient colorectal carcinomas achieve clinical benefit from immune checkpoint inhibitor therapy and are microsatellite instability-high. JCO Precis. Oncol. https://doi.org/10.1200/PO.18.00321 (2019).
Tikidzhieva, A. et al. Microsatellite instability and beta2-microglobulin mutations as prognostic markers in colon cancer: results of the FOGT-4 trial. Br. J. Cancer 106, 12391245 (2012).
doi: 10.1038/bjc.2012.53
Barrow, P. et al. Confirmation that somatic mutations of beta-2 microglobulin correlate with a lack of recurrence in a subset of stage II mismatch repair deficient colorectal cancers from the QUASAR trial. Histopathology 75, 236–246 (2019).
pubmed: 31062389 pmcid: 6772160 doi: 10.1111/his.13895
Busch, E. et al. Beta-2-microglobulin mutations are linked to a distinct metastatic pattern and a favorable outcome in microsatellite-unstable stage IV gastrointestinal cancers. Front. Oncol. 11, 669774 (2021).
pubmed: 34168989 pmcid: 8219238 doi: 10.3389/fonc.2021.669774
Germano, G. et al. CD4 T cell-dependent rejection of beta-2 microglobulin null mismatch repair-deficient tumors. Cancer Discov. 11, 1844–1859 (2021).
pubmed: 33653693 doi: 10.1158/2159-8290.CD-20-0987
de Vries, N. L. et al. γδ T cells are effectors of immunotherapy in cancers with HLA class I defects. Nature 613, 743–750 (2023).
pubmed: 36631610 pmcid: 9876799 doi: 10.1038/s41586-022-05593-1
Marabelle, A., Aspeslagh, S., Postel-Vinay, S. & Soria, J. C. JAK mutations as escape mechanisms to anti-PD-1 therapy. Cancer Discov. 7, 128–130 (2017).
pubmed: 28167612 doi: 10.1158/2159-8290.CD-16-1439
Bayle, A. et al. ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe. Ann. Oncol. 34, 934–945 (2023).
pubmed: 37406812 doi: 10.1016/j.annonc.2023.06.011
Genomics England. The 100,000 Genomes Project. https://www.genomicsengland.co.uk/initiatives/100000-genomes-project (2024).
The German Federal Ministry of Health. GenomeDE — National Strategy for Genomic Medicine. https://www.bundesgesundheitsministerium.de/en/en/international/european-health-policy/genomde-en.html (2024).
The US National Cancer Institute Pan-Cancer Atlas. https://gdc.cancer.gov/about-data/publications/pancanatlas (2024).
Maruvka, Y. E. et al. Analysis of somatic microsatellite indels identifies driver events in human tumors. Nat. Biotechnol. 35, 951–959 (2017).
pubmed: 28892075 pmcid: 9123850 doi: 10.1038/nbt.3966
Marcus, L. et al. FDA approval summary: pembrolizumab for the treatment of tumor mutational burden-high solid tumors. Clin. Cancer Res. 27, 4685–4689 (2021).
pubmed: 34083238 pmcid: 8416776 doi: 10.1158/1078-0432.CCR-21-0327

Auteurs

Jan Budczies (J)

Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany. jan.budczies@med.uni-heidelberg.de.
Translational Lung Research Center (TLRC) Heidelberg, Member of the German Center for Lung Research (DZL), Heidelberg, Germany. jan.budczies@med.uni-heidelberg.de.
Center for Personalized Medicine (ZPM), Heidelberg, Germany. jan.budczies@med.uni-heidelberg.de.

Daniel Kazdal (D)

Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
Translational Lung Research Center (TLRC) Heidelberg, Member of the German Center for Lung Research (DZL), Heidelberg, Germany.
Center for Personalized Medicine (ZPM), Heidelberg, Germany.

Michael Menzel (M)

Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
Center for Personalized Medicine (ZPM), Heidelberg, Germany.

Susanne Beck (S)

Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
Center for Personalized Medicine (ZPM), Heidelberg, Germany.

Klaus Kluck (K)

Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
Center for Personalized Medicine (ZPM), Heidelberg, Germany.

Christian Altbürger (C)

Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
Center for Personalized Medicine (ZPM), Heidelberg, Germany.

Constantin Schwab (C)

Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
Center for Personalized Medicine (ZPM), Heidelberg, Germany.

Michael Allgäuer (M)

Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
Center for Personalized Medicine (ZPM), Heidelberg, Germany.

Aysel Ahadova (A)

Department of Applied Tumour Biology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
Clinical Cooperation Unit Applied Tumour Biology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Matthias Kloor (M)

Department of Applied Tumour Biology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
Clinical Cooperation Unit Applied Tumour Biology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Peter Schirmacher (P)

Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
Center for Personalized Medicine (ZPM), Heidelberg, Germany.

Solange Peters (S)

Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne University, Lausanne, Switzerland.

Alwin Krämer (A)

Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.

Petros Christopoulos (P)

Translational Lung Research Center (TLRC) Heidelberg, Member of the German Center for Lung Research (DZL), Heidelberg, Germany.
Department of Thoracic Oncology, Thoraxklinik and National Center for Tumour Diseases at Heidelberg University Hospital, Heidelberg, Germany.

Albrecht Stenzinger (A)

Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany. albrecht.stenzinger@med.uni-heidelberg.de.
Translational Lung Research Center (TLRC) Heidelberg, Member of the German Center for Lung Research (DZL), Heidelberg, Germany. albrecht.stenzinger@med.uni-heidelberg.de.
Center for Personalized Medicine (ZPM), Heidelberg, Germany. albrecht.stenzinger@med.uni-heidelberg.de.

Classifications MeSH